Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AbbVie’s Imbruvica approved for Waldenstrom’s macroglobulinemia in EU

AbbVie’s Imbruvica approved for Waldenstrom’s macroglobulinemia in EU

13th July 2015

AbbVie has received European Commission approval for Imbruvica to be used as a treatment for the rare form of cancer known as Waldenstrom's macroglobulinemia.

The drug has been approved as a means of combating the slow-growing blood cancer in adult patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy.

In clinical trials, it has shown good response levels and improvements in survival rates, making it a potentially useful therapy for a condition for which there are few available options.

Imbruvica is jointly developed and commercialised in the US by AbbVie subsidiary Pharmacyclics and Janssen. In Europe, Janssen holds the marketing authorisation and its affiliates handle the product's marketing.

Wulff-Erik von Borcke, president of Pharmacyclics, said: "The European Commission approval of Imbruvica as the first and only agent approved for patients with Waldenstrom's macroglobulinemia across the EU underscores its value for patients with serious medical needs, unaddressed so far."

AbbVie completed its takeover of Pharmacyclics in May 2015 and will be working closely with the company to develop new oncology innovations in future.ADNFCR-8000103-ID-801794069-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.